Skip to main content Accessibility help

Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial

Published online by Cambridge University Press:  02 January 2018

Bjarte Stubhaug
Haukeland University Hospital, Heise Bergen HF, Bergen
Stein Atle Lie
Research Centre for Health Promotion, Faculty of Psychology, University of Bergen, Bergen
Holger Ursin
Research Centre for Health Promotion, Faculty of Psychology, University of Bergen, Bergen
Hege R. Eriksen
Department of Education and Health Promotion & Research Centre for Health Promotion, University of Bergen, Bergen, Norway
Rights & Permissions[Opens in a new window]



Single interventions in chronic fatigue syndrome have shown only limited effectiveness, with few studies of comprehensive treatment programmes.


To examine the effect of a comprehensive cognitive-behavioural treatment (CCBT) programme compared with placebo-controlled mirtazapine medication in patients with chronic fatigue, and to study the effect of combined medication and CCBT.


A three-armed randomised clinical trial of mirtazapine, placebo and a CCBT programme was conducted to investigate treatment effect in a patient group (n=72) with chronic fatigue referred to a specialist clinic. The CCBT programme was compared with mirtazapine or placebo therapy for 12 weeks, followed by 12 weeks treatment with a mixed crossover-combination design. Assessments were done at 12 weeks and 24 weeks.


By 12 weeks the treatment effect was significantly better in the group initially receiving CCBT, as assessed with the Fatigue Scale (P=0.014) and the Clinical Global Impression Scale (P=0.001). By 24 weeks the treatment group initially receiving CCBT for 12 weeks followed by mirtazapine for 12 weeks showed significant improvement compared with the other treatment groups on the Fatigue Scale (P < 0.001) and the Clinical Global Impression Scale (P=0.002). Secondary outcome measures showed overall improvement with no significant difference between treatment groups.


Multimodal interventions may have positive treatment effects in chronic fatigue syndrome. Sequence of interventions seem to be of importance.

Copyright © Royal College of Psychiatrists, 2008 

Neurasthenia as a medical term and diagnosis has been known since the 1870s, describing the ill-explained conditions of fatigue, fatiguability, muscular weakness and mental hypersensitivity. Reference Beard1 Since 1980 the labels ‘chronic fatigue syndrome’ and ‘myalgic encephalopathy’ have dominated the international debate and the research in this field, with several different case definitions. Reference Holmes, Kaplan, Gantz, Komaroff, Schonberger, Straus, Jones, Dubois, Cunningham-Rundles and Pahwa2Reference Fukuda, Straus, Hickie, Sharpe, Dobbins and Komaroff4 Systematic reviews of all interventions for treatment and management of chronic fatigue syndrome demonstrate mixed results in effectiveness. Reference Whiting, Bagnall, Sowden, Cornell, Mulrow and Ramirez5,Reference Chambers, Bagnall, Hempel and Forbes6 Behavioural interventions, graded exercise and cognitive–behavioural therapy appear to reduce symptoms and improve function. Most studies report only minor systematic effects of single-treatment regimens in chronic fatigue.

We wanted to examine the possible effects of a comprehensive cognitive–behavioural treatment (CCBT) programme compared with medication, and also the effect of this programme combined with medication. We had found sleep disturbance and depressive symptoms to be prevalent comorbid symptoms in neurasthenia, Reference Stubhaug, Tveito, Eriksen and Ursin7 as also reported in chronic fatigue. Reference Hickie, Lloyd, Wakefield and Parker8 Mirtazapine was chosen as the trial medication because of its positive effect on normal sleep Reference Winokur, Sateia, Hayes, Bayles-Dazet, MacDonald and Gary9,Reference Aslan, Isik and Cosar10 and positive effect on depressive symptoms. Reference Kasper11Reference Freynhagen, Muth-Selbach, Lipfert, Stevens, Zacharowski, Tölle and von Giesen13 We have not found any previous study of mirtazapine in neurasthenia or chronic fatigue syndrome, but for fibromyalgia positive effects have been reported for pain, sleep complaints and depression. Reference Samborski, Lezanska-Szpera and Rybakowski14


The clinical study population consisted of 72 patients with chronic fatigue complaints, fulfilling ICD–10 research criteria for neurasthenia (code F48.0). 15 Illness definition was operationalised by examining ICD–10 criteria. These diagnostic criteria are the presence of persistent and distressing feelings of exhaustion after minor mental effort or of fatigue after minor physical effort, accompanied by one or more of the following symptoms: muscular aches or pains; dizziness; tension headache; sleep disturbance; inability to relax; and irritability. There should be an inability to recover through rest, relaxation or enjoyment; the duration should exceed 3 months, and there should be no organic mental disorder, affective disorder, or panic or generalised anxiety disorder. The included patients satisfied these ICD–10 criteria, allowing for mild depressive or anxiety symptoms clinically evaluated to be independent of or secondary to fatigue symptoms. The criteria for chronic fatigue syndrome, specified by the Centers for Disease Control (CDC), Reference Fukuda, Straus, Hickie, Sharpe, Dobbins and Komaroff4 and the Oxford group Reference Sharpe, Archard, Banatvala, Borysiewicz, Clare, David, Edwards, Hawton, Lambert, Lane, McDonald, Mowbray, Pearson, Peto, Preedy, Smith, Smith, Taylor, Tyrrell, Wessely and White3 were also examined in this population: 65 of the 72 patients fulfilled case definition by the Oxford (British) criteria and 29 patients fulfilled the CDC (US) criteria.

The trial participants were recruited during 2001 from a specialist clinic in the catchment area of the study hospital (population 100 000, mixed suburban and rural) situated on the west coast of Norway, partly by referral from general practitioners to the psychosomatic out-patient clinic for evaluation and treatment of fatigue complaints (n=44), and partly by interviews at the specialist clinic (n=28) after positive screening of fatigue by questionnaire in the waiting rooms of general practitioners in the area. The two different subgroups (referred patients v. screened patients) did not differ on most of the demographic or outcome variables. Reference Stubhaug, Tveito, Eriksen and Ursin7

Patients went through structured interviews and clinical evaluations, including somatic and laboratory investigations. The interviews and assessments were done using the Schedules for Clinical (SCAN) 16 structured interview schedules, checklists for neurasthenia and chronic fatigue syndrome case definitions, in addition to general medical evaluation. Patients fulfilling inclusion criteria were consecutively assigned ascending numbers and randomised into two different treatment groups (CCBT or medication) by concealed randomisation at an external research site, by means of randomisation tables. The further randomisation of medication into mirtazapine and placebo was done by assigning the patients consecutively to mirtazapine/placebo medication by concealed randomisation in a double-blind trial.


Fatigue and clinical global impression of severity were the primary outcome measurements in this trial; depression, quality of life, general health, illness perceptions and cardiorespiratory fitness were secondary measures.


The Fatigue Scale Reference Chalder, Berelowitz, Pawlikowska, Watts, Wessely, Wright and Wallace17 is a self-rating scale developed to measure the severity of fatigue. The scale has been found to be both reliable and valid.

General health status

General health was assessed by subjective health complaints, measured by the Subjective Health Complaint inventory (SHC). Reference Eriksen, Ihlebaek and Ursin18 This consists of 29 items on subjective somatic and psychological complaints experienced during the past 30 days. This questionnaire has been tested and has satisfactory validity and reliability. Reference Eriksen, Ihlebaek and Ursin18 Severity was scored on a four-point scale, from 0 (no complaints) to 3 (severe complaints).

Quality of life

Health-related quality of life was measured using the generic health status measure, the 36-item Short Form Health Survey (SF–36) Reference Ware, Snow and Kosinski19 for health situations during the past 4 weeks; the Norwegian version of the instrument was used. Reference Loge, Kaasa, Hjermstad and Kvien20 The SF–36 is a generic quality of life scale consisting of 36 items describing eight dimensions, which are aggregated to one physical and one mental health component. Reference Ware and Kosinski21

Clinical Global Impression

The Clinical Global Impression (CGI) Reference Guy22 dimensions of severity of illness (CGI–S) and improvement (CGI–I) were used, rated on a seven-point scale. Severity of illness was rated within the past week; global improvement was rated since admission to the study. Severity was assessed by clinical assessment, whereas CGI–I scores were based on patients' self-reports. The CGI–S and CGI–I correlation was analysed.


Symptoms of depression were rated using the 21-item Hamilton Rating Scale for Depression (HRSD). Reference Hamilton23,Reference Hamilton24

Illness perception

The Revised Illness Perceptions Questionnaire (IPQ–R) Reference Moss-Morris, Weinman, Petrie, Horne, Cameron and Buick25 was used to measure patients' illness perceptions. This questionnaire has demonstrated good reliability and validity across several illness groups and includes eight cognitive dimensions.

Cardiorespiratory fitness

Cardiorespiratory fitness was assessed by the Åstrand–Ryhming test (indirect test of maximal oxygen uptake (VO2max)), Reference Astrand and Ryhming26 performed on an ergometer bicycle.

Safety assessments

Safety assessments included a full clinical examination prior to inclusion in the trial, and spontaneously reported adverse events and measurements of vital signs and weight at each scheduled efficacy evaluation, in addition to laboratory tests. Adverse events were coded in the Medical Dictionary for Regulatory Activities (MedDRA) system, Reference Brown, Wood and Wood27 using the preferred term as the unit of registration.

Timing of assessments

Assessments were done at baseline, 12 weeks and 24 weeks (end of treatment). Assessments at 12 weeks, after completion of the CCBT programme or medication/placebo course, registered treatment effects in three groups: CCBT v. mirtazapine medication v. placebo medication. Assessments at 24 weeks included four groups: 12 weeks CCBT followed by 12 weeks mirtazapine; 12 weeks CCBT followed by 12 weeks placebo; mirtazapine (24 weeks) combined with 0+12 weeks CCBT; placebo medication (24 weeks) combined with 0+12 weeks CCBT. Assessments were done mainly by self-report questionnaires and measures.


The interventions, administered by a team comprising a psychiatrist, physiotherapists and a psychiatric nurse, were as follows:

  1. (a) A comprehensive cognitive–behavioural treatment programme for 12 weeks, consisting of two 1.5 h sessions of group therapy per week (cognitive–behavioural therapy 1.5 h, body awareness therapy 1.5 h), combined with a self-managed exercise programme with individually set daily exercise goals (minimal to mild/moderate), using an exercise diary for planned and executed activity.

  2. (b) Medication (double-blind) for 12 weeks: mirtazapine (individually adjusted dosage to adverse events; standard dose 15–45 mg, allowing lower dose) v. inactive placebo (medication was dispensed for 2-week periods from the hospital pharmacy; tablets taken by the patients were registered and the returned tablets counted by the pharmacist).

After the initial 12 weeks, treatment was continued in a combined crossover and treatment-combination design. Patients on medication (mirtazapine or placebo) received the CCBT programme for the next 12 weeks; patients having completed the CCBT programme received medication (mirtazapine or placebo) for the following 12 weeks.

The cognitive–behavioural therapy group sessions (12 sessions of 1.5 h) were conducted by a team of a trained psychiatrist and a psychiatric nurse, using a semi-structured therapy manual with assigned topics for each session, including weekly reports of exercise tasks. Body awareness therapy emphasises increased awareness of bodily sensations, breathing, posture, balance and muscular tension, and focuses on how increased body awareness can help gain greater control over physical and mental tension. Reference Skatteboe, Friis, Hope and Vaglum28 Treatment was conducted by physiotherapists trained in this therapy.

Statistical methods

The sample size needed was based on statistical calculation of presumed treatment effect of one standard deviation (4.0/33) from mean value of Fatigue Scale score, Reference Chalder, Berelowitz, Pawlikowska, Watts, Wessely, Wright and Wallace17 level of significance 0.05, power 0.80; the s.d. being calculated from a pilot population of 20 patients with neurasthenia (mean value 23.6/33, variance 16.24, s.d.=4.03). The target sample size for a three- and four-armed study was calculated to be 64 (16×4). The actual sample size (n=72) exceeded the minimum number. To model the structure of the therapy in the study, we designed the covariates to account for changes in the status of the individuals. Thus, at baseline all individuals had the same status, whereas at 12 weeks there were three categories (mirtazapine, placebo and CCBT) and at 24 weeks there were four categories (mirtazapine 24 weeks + CCBT 12 weeks; placebo 24 weeks + CCBT 12 weeks; CCBT 12 weeks + mirtazapine 12 weeks; and CCBT 12 weeks + placebo 12 weeks). To account for the repeated measures for the participants, individuals were entered in the model as a random variable (with an unstructured covariance structure). Other variables were entered as fixed effects. Outcome analyses were done using PROC MIXED in SAS version 8.0 for Windows. Other analyses were done in SPSS version 13.0. Data analysis was completed on an intention-to-treat basis, with last observation carried forward (LOCF) as end value in cases of protocol violation or premature discontinuation. We also analysed the data omitting the missing observations, and found virtually the same results as when using LOCF; these results are therefore not presented.


The study was approved by the Regional Ethics Committee, the Norwegian Social Science Data Services (NSD) and the Norwegian Medicines Agency. The trial was registered with NSD prior to any patient inclusion. All participants were given written information about the trial and gave formal consent about participation. Prospectively defined stopping rules were medical conditions warranting treatment, medication conflicting with study protocol, and serious adverse events due to or suspected to be caused by medication.

Masking (blinding)

Medication was provided in the form of capsules of 15 mg mirtazapine or inactive substance. The capsules were identical in appearance, with no smell or taste. Allocation to active medication or placebo was concealed by hiding the allocation code in a locked envelope at the clinical site (in case of an emergency requiring breaking of the code), to be returned unopened to the manufacturer/provider by the end of the study. No emergency need occurred. The code was broken by the medication provider at the end of the follow-up period, after 1-year follow-up investigations, questionnaire completion and data collection. Masking seemed successful among participants by reports of effect and adverse events in both groups. There was no evidence by clinicians or assessors of systematic impression of non-concealment. All data were entered into the research database prior to breaking the allocation code. The trial statistician executed the analysis using anonymous data.


Patients were recruited and included consecutively over a period of 12 months. The treatment programme (24 weeks) was conducted through two periods, with a 6-month interval. Forty-three patients took part in the first programme and 29 in the second (total n=72). No significant difference was observed between treatment groups on baseline values of outcome measures (Table 1).

Table 1 Characteristics of the study groups at baseline

Mirtazapine (24 weeks) + CCBT (12 weeks) (n=25) Placebo (24 weeks) + CCBT (12 weeks) (n=24) CCBT (12 weeks) + Mirtazapine (12 weeks) (n=11) CCBT (12 weeks) + Placebo (12 weeks) (n=12) Total (n=72)
    Male 6 3 2 2 13
    Female 19 21 9 10 59
Fatigue Scale score: mean (s.d.) 24.76 (4.53) 25.54 (3.87) 24.91 (5.96) 24.33 (4.75) 24.97 (4.53)
CGI score: mean (s.d.) 4.84 (0.80) 4.92 (0.72) 5.18 (0.60) 5.27 (0.79) 4.99 (0.75)
SHC total score: mean (s.d.) 23.56 (9.29) 26.02 (10.55) 27.36 (13.00) 27.00 (10.10) 25.54 (10.35)
Age, years: mean (s.d.) 44.92 (8.41) 44.96 (8.46) 47.18 (10.64) 51.17 (7.26) 46.32 (8.75)
SF—36 score: mean (s.d.)
    Physical 26.39 (9.70) 30.65 (12.16) 31.13 (10.54) 27.74 (12.92) 28.94 (11.31)
    Mental 43.37 (11.31) 34.32 (11.98) 37.19 (13.05) 44.93 (14.91) 39.37 (13.06)
HRSD score: mean (s.d.) 13.32 (4.79) 15.92 (3.66) 14.00 (2.00) 14.64 (3.04) 14.51 (3.92)
CRF, O2 ml/kg: mean (s.d.) 27.14 (7.16) 26.18 (5.30) 24.78 (6.05) 22.62 (6.44) 25.77 (6.35)

A total of 119 patients were eligible for the trial; 32 were excluded because of somatic or psychological disorders, and 15 people were unwilling to use medication as required by the study protocol. Baseline and treatment measurement data were available from 72 participants (Fig. 1).

Fig. 1 Study profile. CCBT, comprehensive cognitive–behavioural treatment; LOCF, last observation carried forward.

There were significant improvements at 12 weeks in the CCBT group compared with the mirtazapine and placebo groups in terms of Fatigue Scale (P=0.014) and CGI (P=0.001) ratings (Table 2). End-of-treatment data at 24 weeks showed statistically significant improvement in the treatment group where the initial 12 weeks of CCBT was followed by 12 weeks of mirtazapine, compared with the reference group, which received placebo for 24 weeks and CCBT for the last 12 weeks. The improvement was significant for scores on the Fatigue Scale (P<0.001), CGI (P=0.002) and HRSD (P=0.018), and was accompanied by a significant reduction in scores on the SHC, pseudoneurology sub-scale (P=0.011) (Table 3). Measures of health-related quality of life, using the SF–36 (two-component scale), showed significant improvement on the SF–36 mental sub-scale by the end of treatment (24 weeks) in the treatment group taking mirtazapine for 24 weeks plus CCBT for 12 weeks (P=0.045) (Table 4).

Table 2 Difference between the therapies: results from a mixed model

CGI score Fatigue Scale score HRSD score CRF, O2 ml/kg
n Mean (95% CI) P Mean (95% CI) P Mean (95% CI) P Mean (95% CI) P
12 weeks 0.005a 0.047a 0.64a 0.25a
    Mirtazapine 25 4.0 (3.7-4.3) 0.046 22.7 (21.4-24.1) 0.34 12.6 (11.4-13.8) 0.36 26.6 (23.5-29.7) 0.29
    CCBT 23 3.7 (3.1-4.2) 0.001 21.0 (18.1-24.0) 0.014 12.9 (10.1-15.7) 0.54 24.6 (17.4-31.9) 0.10
    Placebo 24 4.4 (3.9-4.9) Ref. 23.7 (21.0-26.5) Ref. 13.5 (10.9-16.1) Ref. 29.5 (22.6-36.4) Ref.
24 weeks 0.001a 0.004a 0.075a 0.75a
    Mirtazapine + CCBT 25 4.6 (4.3-4.8) 0.40 23.7 (22.4-25.0) 0.66 12.7 (11.6-13.9) 0.13 27.6 (24.8-30.4) 0.64
    CCBT + placebo 12 3.8 (3.2-4.4) 0.045 23.3 (20.1-26.5) 0.55 14.0 (10.8-17.1) 0.74 25.0 (17.0-33.0) 0.31
    CCBT + mirtazapine 11 3.4 (2.8-4.0) 0.002 18.7 (15.4-22.0) <0.001 10.8 (7.7-13.9) 0.018 26.0 (17.7-34.2) 0.44
    Placebo + CCBT 24 4.4 (3.9-4.9) Ref. 24.2 (21.4-27.1) Ref. 14.4 (11.8-17.1) Ref. 29.0 (22.0-36.0) Ref.

Table 3 Difference between the therapies as assessed by the Subjective Health Complaint inventory: results from a mixed model

SHC score
Total Musculoskeletal Pseudoneurology Gastrointestinal
n Mean (95% CI) P Mean (95% CI) P Mean (95% CI) P Mean (95% CI) P
24 weeks 0.58a 0.38a 0.043a* 0.37a
    Mirtazapine + CCBT 25 24.1 (21.7-26.6) 0.99 9.9 (8.8-11.1) 0.37 7.2 (6.4-8.0) 0.031 4.5 (3.6-5.4) 0.081
    CCBT + placebo 12 24.5 (19.4-29.6) 0.88 10.2 (8.1-12.3) 0.34 7.9 (6.3-9.5) 0.34 3.8 (1.9-5.8) 0.44
    CCBT + mirtazapine 11 20.6 (15.3-25.9) 0.23 8.2 (6.0-10.3) 0.38 6.4 (4.8-8.1) 0.011* 3.6 (1.6-5.6) 0.60
    Placebo + CCBT 24 24.1 (20.1-28.1) Ref. 9.2 (7.5-10.9) Ref. 8.7 (7.5-10.0) Ref. 3.0 (1.5-4.5) Ref.

Table 4 Difference between the therapies as assessed by the 36-item Short Form Health Survey: results from a mixed model

SF—36 Mental sub-scale SF—36 Physical sub-scale
n Mean (95% CI) P Mean (95% CI) P
24 weeks 0.19a 0.34a
    Mirtazapine + CCBT 25 42.6 (39.1-46.0) 0.045* 28.4 (25.4-31.4) 0.20
    CCBT + placebo 12 41.0 (33.7-48.2) 0.19 27.1 (21.6-32.5) 0.12
    CCBT + mirtazapine 11 37.1 (29.4-44.9) 0.76 31.0 (25.2-36.8) 0.89
    Placebo + CCBT 24 35.9 (30.2-41.6) Ref. 31.4 (27.0-35.8) Ref.

Data showed no consistent overall change in illness perception in the study population from baseline to end of study (24 weeks). A paired t-test showed significant changes in the illness perception dimensions of cyclical timeline (P<0.001), illness consequences (P=0.002) and illness coherence (P=0.002), irrespective of treatment group. The one-way analysis of variance (ANOVA; SPSS version 13.0) showed a difference between groups on the illness perception of cyclical timeline (P=0.028), but the post hoc comparisons (Sheffé) showed no difference between specific treatment groups.

Subjective global improvement of fatigue complaints was registered by self-report questionnaire of changes during treatment, CGI–I (7-points scale) and was correlated with the CGI–S assessment by clinician. Correlation analysis (n=60) showed a significant correlation: r=0.68 (P<0.0001). Self-reported CGI–I scores showed an overall increase (mean difference 0.70, P<0.001), indicating improvement across the treatment groups, but with no significant difference in improvement between groups when analysed by one-way ANOVA or post hoc comparison.

Cardiorespiratory fitness, assessed by indirect measurement of maximal oxygen uptake, showed a tendency towards overall improvement in all groups following the total treatment programme (P=0.08 at 12 weeks, P=0.07 at 24 weeks, compared with baseline values), in an unadjusted model with time effect only.

All patients taking mirtazapine and 45% of patients taking placebo reported at least one adverse event, irrespective of dosage or length of adverse event. The four most frequently reported adverse events in the mirtazapine group were sedation (56%), increased appetite (31%), weight increase (33%) and restless legs syndrome (19%). In the placebo-treated group, the most frequently reported adverse events were headache (17%), sedation (11%), weight increase (11%) and insomnia (11%). The drug-associated adverse events (i.e. events occurring in at least 5% of patients and at a rate at least twice that of the placebo group) were sedation, increased appetite, weight increase, restless legs syndrome and constipation (Fig. 2).

Fig. 2 Adverse events.

There was no serious change in vital signs (except weight increase, reported as an adverse event) or in laboratory parameters (including endocrine and electrolyte measures) in the total study population, and no systematic difference between study groups or between patients with active medication and patients on placebo treatment.

Patients violating protocol (by stopping taking medication or using adjunctive medication beyond protocol) were allowed to continue in the treatment programme, but data for analysis of outcome and treatment effect were systematically based on LOCF data at the time of protocol violation. Other missing data from premature discontinuation were analysed by conservative model/intention-to-treat analysis.

A source of bias and imprecision of the study findings was the outcome assessment (CGI–S) done by the psychiatrist (B.S.) responsible for treatment interventions. This was resolved by the use of self-report questionnaires on other outcome measurements, including self-reports of global improvement (CGI–I), which was correlated with the CGI–S measurements by the clinical assessor, showing significant correlation (r=0.68, P<0.0001).


This study has a complex design, and some of the findings can be questioned in view of both the complex combination of interventions and the small number in each treatment group. Power analysis of the results supports the significance of our positive findings, although type 2 errors cannot be ruled out for some of the negative findings owing to the low number of participants.

The findings from the study indicate that a comprehensive treatment programme based on multimodal interventions may have positive treatment effects in patients with chronic fatigue and neurasthenia, being superior to medication or placebo alone and being more effective as part of a combination treatment. The 12-week comprehensive treatment programme (cognitive group therapy, body awareness therapy and graded exercise) was significantly more effective than mirtazapine or placebo. The addition of mirtazapine (12 weeks) to the initial comprehensive treatment sequence showed a further treatment effect significantly superior (P<0.001) to the other combinations of treatment, including the opposite sequence of medication first, followed by the comprehensive treatment programme. It seems that the timing of the different intervention sequences is of importance: our findings indicate that an initial non-pharmacological ‘priming’ by a cognitive-oriented treatment programme prior to medication gives the best treatment effect. This is consistent with the results of a simulation analysis of the self-regulation of fatigue, in which the most effective treatment is stage-dependent with an initial period of delay before active intervention. Reference van Mens-Verhulst, van Dijkum, van Kuijk and Lam29 It is possible that an introductory treatment phase with a cognitive–behavioural approach, focusing on an integrative model of fatigue, emphasising cognitive appraisal and body awareness, and the importance of regular, adjusted physical activity, brings better understanding of and better compliance with pharmacological treatment.

The findings are consistent for the primary outcome measures Fatigue Scale and CGI at 12 weeks and 24 weeks, and also for the HRSD by the end of the study at 24 weeks. Subjective Health Complaints showed a significant difference favouring the combination CCBT followed by mirtazapine on the pseudoneurological items scale, including tiredness (as would be expected, as fatigue symptoms showed reduction as measured by the Fatigue Scale). Quality of life outcome measures (SF–36) showed a slight but significant effect on mental health on the two-component aggregated scale, favouring the group using mirtazapine for 24 weeks. This effect on general mental health could be related to the active medication mirtazapine's positive effect on sleep difficulties reported by most patients, in addition to the antidepressant effect and general psychotropic action.

Illness perceptions were subject to change during the treatment programme. Many patients with fatigue complaints showed activity-avoidant behaviour based on misperceptions of their illness. These illness perceptions were the basis for our cognitive therapeutic approach aiming at modifying avoidance behaviour and excessive rest. Our data showed a reduction in illness perceptions on the dimensions of cyclical timeline, illness consequence and illness coherence, indicating a change in illness perceptions towards a more open-ended mental picture of the fatigue symptoms and neurasthenic illness, and a less rigid model of the condition, accepting it more as a complex disorder than as a disease with a single cause. These changes were found across the different treatment groups – as would be expected, since all groups received the cognitive treatment intervention.

Our study indicates that an effective treatment of chronic fatigue syndrome and neurasthenia should be based on a broad and comprehensive approach, using and combining treatment interventions already proved to be effective, with particular emphasis on the timing and sequence of the various interventions, in addition to the active participation and exercise by the patients themselves.


Declaration of interest

The trial received an unrestricted grant from Organon AS, who provided the placebo-controlled medication.


1 Beard, G. Neurasthenia, or nervous exhaustion. Boston Med Surg J 1869; 3: 217–21.Google Scholar
2 Holmes, GP, Kaplan, JE, Gantz, NM, Komaroff, AL, Schonberger, LB, Straus, SE, Jones, SF, Dubois, RE, Cunningham-Rundles, C, Pahwa, S. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988; 108: 387–9.CrossRefGoogle ScholarPubMed
3 Sharpe, MC, Archard, LC, Banatvala, JE, Borysiewicz, LK, Clare, AW, David, A, Edwards, RH, Hawton, KE, Lambert, HP, Lane, RJ, McDonald, EM, Mowbray, JF, Pearson, DJ, Peto, TEA, Preedy, VR, Smith, AP, Smith, DJ, Taylor, DJ, Tyrrell, DA, Wessely, S, White, PD. A report – chronic fatigue syndrome: guidelines for research. J R Soc Med 1991; 84: 118–21.Google ScholarPubMed
4 Fukuda, K, Straus, SE, Hickie, I, Sharpe, MC, Dobbins, JG, Komaroff, A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953–9.CrossRefGoogle ScholarPubMed
5 Whiting, P, Bagnall, AM, Sowden, AJ, Cornell, JE, Mulrow, CD, Ramirez, G. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review. JAMA 2001; 286: 1360–8.CrossRefGoogle ScholarPubMed
6 Chambers, D, Bagnall, AM, Hempel, S, Forbes, C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med 2006; 99: 506–20.Google Scholar
7 Stubhaug, B, Tveito, TH, Eriksen, HR, Ursin, H. Neurasthenia, subjective health complaints and sensitization. Psychoneuroendocrinology 2005; 30: 1003–9.CrossRefGoogle ScholarPubMed
8 Hickie, I, Lloyd, A, Wakefield, D, Parker, G. The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry 1990; 156: 534–40.CrossRefGoogle ScholarPubMed
9 Winokur, A, Sateia, MJ, Hayes, JB, Bayles-Dazet, W, MacDonald, MM, Gary, KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biol Psychiatry 2000; 48: 75–8.CrossRefGoogle ScholarPubMed
10 Aslan, S, Isik, E, Cosar, B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep 2002; 25: 677–9.CrossRefGoogle ScholarPubMed
11 Kasper, S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997; 17 (suppl 1): S1928.CrossRefGoogle ScholarPubMed
12 Holm, KJ, Markham, A. Mirtazapine: a review of its use in major depression. Drugs 1999; 57: 607–31.CrossRefGoogle ScholarPubMed
13 Freynhagen, R, Muth-Selbach, U, Lipfert, P, Stevens, MF, Zacharowski, K, Tölle, TR, von Giesen, JH. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006; 22: 257–64.CrossRefGoogle ScholarPubMed
14 Samborski, W, Lezanska-Szpera, M, Rybakowski, JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004; 37: 168–70.CrossRefGoogle ScholarPubMed
15 World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. WHO, 1993.Google Scholar
16 World Health Organization. Schedules for Clinical Assessment in Neuropsychiatry (SCAN). WHO, 1992.Google Scholar
17 Chalder, T, Berelowitz, G, Pawlikowska, T, Watts, L, Wessely, S, Wright, D, Wallace, EP. Development of a fatigue scale. J Psychosom Res 1993; 37: 147–53.CrossRefGoogle ScholarPubMed
18 Eriksen, HR, Ihlebaek, C, Ursin, H. A scoring system for subjective health complaints (SHC). Scand J Public Health 1999; 27: 6372.CrossRefGoogle Scholar
19 Ware, JE, Snow, KK, Kosinski, M. SF-36 Health Survey Manual and Interpretation Guide. Quality Metric Inc, 2000.Google Scholar
20 Loge, JH, Kaasa, S, Hjermstad, MJ, Kvien, TK. Translation and performance of the Norwegian SF-36 Health Survey in patients with rheumatoid arthritis. I. Data quality, scaling assumptions, reliability, and construct validity. J Clin Epidemiol 1998; 51: 1069–76.CrossRefGoogle ScholarPubMed
21 Ware, JE, Kosinski, M. SF-36 Physical and Mental Health Summary Scales: A Manual for Users of ver 1. Quality Metric Inc, 2001.Google Scholar
22 Guy, W. CGI Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology (Revised) 217–22. National Institute for Mental Health, 1976.Google Scholar
23 Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 5662.CrossRefGoogle Scholar
24 Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–96.CrossRefGoogle ScholarPubMed
25 Moss-Morris, R, Weinman, J, Petrie, KJ, Horne, R, Cameron, LD, Buick, D. The Revised Illness Perception Questionnaire (IPQ-R). Psychol Health 2002; 17: 116.CrossRefGoogle Scholar
26 Astrand, PO, Ryhming, I. A nomogram for calculation of aerobic capacity (physical fitness) from pulse rate during sub-maximal work. J Appl Physiol 1954; 7: 218–21.CrossRefGoogle ScholarPubMed
27 Brown, EG, Wood, L, Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109–17.CrossRefGoogle Scholar
28 Skatteboe, UB, Friis, S, Hope, MK, Vaglum, P. Body awareness group therapy for patients with personality disorders. 1. Description of the therapeutic method. Psychother Psychosom 1989; 51: 1117.CrossRefGoogle ScholarPubMed
29 van Mens-Verhulst, J, van Dijkum, C, van Kuijk, E, Lam, N. The self-regulation of fatigue and associated complaints: an exploratory simulation. Patient Educ Couns 2003; 49: 53–7.CrossRefGoogle ScholarPubMed
Submit a response


No eLetters have been published for this article.

Altmetric attention score

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 173
Total number of PDF views: 196 *
View data table for this chart

* Views captured on Cambridge Core between 02nd January 2018 - 24th January 2021. This data will be updated every 24 hours.

Hostname: page-component-76cb886bbf-kdwz2 Total loading time: 1.31 Render date: 2021-01-24T16:29:56.844Z Query parameters: { "hasAccess": "1", "openAccess": "0", "isLogged": "0", "lang": "en" } Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false }

Send article to Kindle

To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial
Available formats

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial
Available formats

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Cognitive-behavioural therapy v. mirtazapine for chronic fatigue and neurasthenia: randomised placebo-controlled trial
Available formats

Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *